Tracking every rollback, reversal, and overreach — and the path back to the America we know.
President Trump selected Erica Schwartz, former deputy surgeon general and medical doctor, to lead the Centers for Disease Control and Prevention. Schwartz, a retired rear admiral in the U.S. Public Health Service Commissioned Corps, requires Senate confirmation. The CDC has been without permanent leadership for eight months.
The FDA appointed Katherine Szarama as acting director of the Center for Biologics Evaluation and Research, replacing Vinay Prasad. This unit regulates vaccines and biological products for human use. The leadership change may impact vaccine approval processes and biological product oversight.
President Trump signed an executive order directing the FDA to accelerate review of psychedelic drugs including ibogaine for medical treatment. The order aims to speed access to psychedelic-based therapies, particularly for treating post-traumatic stress disorder in military veterans. The reform could expand availability of these treatments to Americans seeking alternative mental health interventions.
President Trump signed an executive order to accelerate research on psychedelic drugs for treating mental health disorders. The order aims to expedite clinical trials and regulatory pathways for these substances. This could expand treatment options for Americans suffering from depression, PTSD, and other mental health conditions.
President Trump withdrew his nomination of Casey Means for Surgeon General and announced Dr. Nicole Saphier, a Fox News contributor and radiologist, as his replacement. This marks Trump's third nominee for the Surgeon General position. The change affects the leadership of the U.S. Public Health Service and sets the direction for federal health policy.